These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 778998)

  • 1. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P; Bathien N; Dumas JL
    Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
    [No Abstract]   [Full Text] [Related]  

  • 3. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
    Truelle JL; Chanelet J; Bastard J; Six P; Emile J
    Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
    Emile J; Chanelet J; Truelle JL; Bastard J
    Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.
    Mentenopoulos G; Katsarou Z; Bostantjopoulou S; Logothetis J
    Clin Neuropharmacol; 1989 Feb; 12(1):23-8. PubMed ID: 2713865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on piribedil in Parkinsonism.
    Lieberman AN; Shopsin B; Brun YL; Boal D; Zolfaghari M
    Adv Neurol; 1975; 9():399-407. PubMed ID: 125032
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piribedil in Parkinson's syndrome: a clinical study.
    Engel J; Granerus AK; Svanborg A
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):223-6. PubMed ID: 183960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
    Borromei A; Manzini A
    Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450
    [No Abstract]   [Full Text] [Related]  

  • 12. Actions of dopaminergic agonists in parkinsonism.
    McDowell FH; Sweet R
    Adv Neurol; 1975; 9():367-71. PubMed ID: 1096573
    [No Abstract]   [Full Text] [Related]  

  • 13. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
    Sweet RD; Wasterlain C; McDowell FH
    Trans Am Neurol Assoc; 1974; 99():258-60. PubMed ID: 4463553
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
    Feigenson JS; Sweet RD; McDowell FH
    Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
    Callaghan N; Fitzpatrick E; O'Mahony JB
    Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term clinical and electrophysiological study of a new dopaminergic agonist in 54 patients with parkinsonism].
    Truelle JL; Chanelet J; Bastard J; Six P; Emile J
    Sem Hop Ther; 1977 Nov; 53(9):453-6. PubMed ID: 341320
    [No Abstract]   [Full Text] [Related]  

  • 20. [Considerations in the drug treatment of parkinsonism (author's transl)].
    Hungerbühler JP; Regli F
    Schweiz Rundsch Med Prax; 1978 Nov; 67(45):1648-57. PubMed ID: 30976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.